Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Li-Ping Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, China. Hauptthemen laut MEDLINE: Benzylisoquinolines, Gefitinib, Proto-Oncogene Proteins c-akt, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, China Postdoctoral Science Foundation, Guangdong Provincial Bureau of Traditional Chinese Medicine.
Abstract (Originalsprache)
Acquired resistance to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, remains a major therapeutic challenge in EGFR‐mutant non‐small cell lung cancer (NSCLC). Here, we report that cepharanthine (CEP), a natural bisbenzylisoquinoline alkaloid, effectively reverses gefitinib resistance through concurrent suppression of the AKT/P70S6K survival axis and activation of the Stimulator of Interferon Genes (STING)‐mediated innate immune pathway. In gefitinib‐resistant H1975 cells (EGFR L858R/T790M), CEP monotherapy significantly inhibited proliferation and induced mitochondrial apoptosis. Notably, CEP synergized with gefitinib to enhance therapeutic efficacy. RNA sequencing and functional validation revealed that CEP activates the STING/TANK‐Binding Kinase 1 (TBK1)/Interferon Regulatory Factor 3 (IRF3) signaling cascade, resulting in robust production of T‐cell chemoattractants C‐X‐C Motif Chemokine Ligand 9 (CXCL9), C‐X‐C Motif Chemokine Ligand 10 (CXCL10), and C‐C Motif Chemokine Ligand 5 (CCL5). Critically, the STING inhibitor H‐151 abolished CEP's antitumor effects in vitro. Our findings reveal a novel dual mechanism action of CEP and nominate it as a potential candidate for overcoming TKI resistance in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, China.
- Northeastern University, Boston, Massachusetts, USA.
- Translational Medicine Research Center, Medical College, Dalian University, Dalian, Liaoning, China.
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- China Postdoctoral Science Foundation
- Guangdong Provincial Bureau of Traditional Chinese Medicine
- Zhuhai Science and Technology Innovation Bureau
- Zhuhai Hospital of Integrated Traditional Chinese & Western Medicine
- Guangdong Province-Provincial Chinese Medicine construction special fund named Traditional Chinese Medicine Inheritance Studio construction project Guangdong C…
- Medical Science and Technology Research Fund of Guangdong Province
- Beijing Chao Enxiang Traditional Chinese Medicine Heritage and Development Foundation
Zitieren
APA
Kang, L. P., Chen, H. H., Lv, T. T., Huang, H. J., Huang, D. H., Chen, Y. Q., & Jiang, Z. B. (2026). Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70298
Vancouver
Kang LP, Chen HH, Lv TT, Huang HJ, Huang DH, Chen YQ, et al. Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70298
BibTeX
@article{Kang2026,
author = {Kang, Li-Ping and Chen, Hui-Hui and Lv, Tong-Tong and Huang, Hua-Jing and Huang, Dong-Hui and Chen, Ying-Qing and Jiang, Ze-Bo},
title = {Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70298}
}
EUVIMED